Portal vein thrombosis may be the first presentation of a hypercoagulable state. We report a case that illustrates a diagnostic approach to show the extent of the splanchnic venous thrombus and to investigate its haematological aetiology. The discussion focused on the association between portal vein thrombosis and myeloproliferative disease and controversies in managing this condition. 
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Case history
A 59 year old woman was admitted to hospital with central abdominal pain, nausea, and copious vomiting that had persisted for 48 hours. She had experienced a similar but less severe episode one month previously but had no other history. On examination she was febrile and there were no stigmata of chronic liver disease. Her spleen was noticeably enlarged to 15 cm below the costal margin. No ascites was present.
Investigation showed her haemoglobin concentration to be 180 g/l, her white blood cell count to be 21 -2 x 109/l (88% neutrophils), and her platelet count to be 600x 109/1. Blood concentrations of urea and electrolytes and serum activity of amylase were normal and liver function tests gave normal results. The concentration of C reactive protein was 46 mg/l (normal range <10 mg/l). Doppler ultrasonography at the referring hospital confirmed pronounced splenomegaly and showed portal, splenic, and superior mesenteric vein thrombosis with normal echogenicity over the liver. Initial management consisted of full heparinisation, opiate analgesia, and venesection.
She was referred for further evaluation. 
Comment
Although the association between myeloproliferative disorders such as polycythaemia rubra vera, essential thrombocythaemia, myelofibrosis and chronic myeloid leukaemia, and hypercoagulable states is well recognised, the incidence of myeloproliferative disorders in patients presenting with splanchnic vein thrombosis may be higher than generally appreciated. In a recent study of adult patients presenting with portal vein thrombosis an underlying myeloprolifera-BMJ VOLUME 300tive disease was diagnosed in almost half of them.' In this prospective series of 33 patients nine had polycythaemia rubra vera and six essential thrombocythaemia. In only half of them, however, would the condition have been diagnosed at presentation from the usual criteria of suggestive full blood count, increased red cell mass, and compatible bone marrow histology. In four patients the diagnosis became apparent only during extended observation at follow up. In three the evidence of a myeloproliferative disorder was the production of erythroid colonies when bone marrow progenitor cells were cultured without added erythropoietin. 
